Education
About Us
Working with TipRanks
Follow Us
Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
RESEARCH TOOLSreports
Total Valuation
Orchestra BioMed Holdings has a market cap or net worth of $109.19M. The enterprise value is $101.81M.
Market Cap$109.19M
Enterprise Value$101.81M
Share Statistics
Orchestra BioMed Holdings has 38,312,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,312,510
Owned by Insiders12.04%
Owned by Institutions34.22%
Financial Efficiency
Orchestra BioMed Holdings’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -60.84%.
Return on Equity (ROE)-0.72
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-60.84%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee39.43K
Profits Per Employee-701.71K
Employee Count70
Asset Turnover0.03
Inventory Turnover1.27
Valuation Ratios
The current PE Ratio of Orchestra BioMed Holdings is -6.18. Orchestra BioMed Holdings’s PEG ratio is 0.18.
PE Ratio-6.18
PS Ratio64.77
PB Ratio4.46
Price to Fair Value4.46
Price to FCF-6.57
Price to Operating Cash Flow-6.58
PEG Ratio0.18
Income Statement
In the last 12 months, Orchestra BioMed Holdings had revenue of 2.76M and earned -49.12M in profits. Earnings per share was -1.48.
Revenue2.76M
Gross Profit2.57M
Operating Income-51.51M
Pretax Income-49.12M
Net Income-49.12M
EBITDA-51.22M
Earnings Per Share (EPS)-1.48
Cash Flow
In the last 12 months, operating cash flow was -47.99M and capital expenditures -180.00K, giving a free cash flow of -48.17M billion.
Operating Cash Flow-47.99M
Free Cash Flow-48.17M
Free Cash Flow per Share-1.26
Dividends & Yields
Orchestra BioMed Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.88
52-Week Price Change-36.67%
50-Day Moving Average4.21
200-Day Moving Average5.46
Relative Strength Index (RSI)36.87
Average Volume (3m)61.09K
Important Dates
Orchestra BioMed Holdings upcoming earnings date is May 9, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 9, 2025
Ex-Dividend Date―
Financial Position
Orchestra BioMed Holdings as a current ratio of 7.95, with Debt / Equity ratio of 3.98%
Current Ratio7.95
Quick Ratio7.94
Debt to Market Cap0.00
Net Debt to EBITDA0.56
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Orchestra BioMed Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Orchestra BioMed Holdings EV to EBITDA ratio is -5.36, with an EV/FCF ratio of -5.94.
EV to Sales99.45
EV to EBITDA-5.36
EV to Free Cash Flow-5.94
EV to Operating Cash Flow-5.95
Balance Sheet
Orchestra BioMed Holdings has $66.93M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$65.09M billion.
Cash & Marketable Securities$66.93M
Total Debt$0.00
Net Cash-$65.09M
Net Cash Per Share-$1.70
Tangible Book Value Per Share$2.05
Margins
Gross margin is 88.55%, with operating margin of -1866.16%, and net profit margin of -1779.71%.
Gross Margin88.55%
Operating Margin-1866.16%
Pretax Margin-1779.71%
Net Profit Margin-1779.71%
EBITDA Margin-1855.76%
EBIT Margin-1866.16%
Analyst Forecast
The average price target for Orchestra BioMed Holdings is $13.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.33
Price Target Upside367.72% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-4.42%
EPS Growth Forecast-12.01%